Non-transfusion-dependent thalassemia encompasses three clinically distinct forms -- beta-thalassaemia intermedia, hemoglobin E/beta-thalassaemia ... endpoint -- a ≥1.0 g/dL increase in mean ...

Non-transfusion-dependent thalassemia encompasses three clinically distinct forms -- beta-thalassaemia intermedia, hemoglobin E/beta-thalassaemia (mild and moderate forms), and al ...

On investigation, he was found to have low hemoglobin (Hb: range ... High-performance liquid chromatography was negative for beta-thalassemia with Hb A 2 of 2.8%, Hb F of 1.4% and no other abnormal Hb ...

This procedure during pregnancy was associated with fewer admissions for pain crises (p=0.032), higher gestational age at delivery ... in patients with severe SCD (45 Hb SS plus 2 Hb Sβ0-thalassemia ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Thalassemia is a genetic blood disorder that affects hemoglobin production, leading to severe anemia and requiring lifelong medical management, including regular blood transfusions. The impact of ...

There were no serious adverse events or treatment-related mortalities. Evidence Rating Level: 2 (Good) Study Rundown: ...

A Thalassemia screening desk has been inaugurated at the NADRA centre in Sukkur on Saturday marking a significant step forwards the fight against the genetic disorder. The desk, established in ...

Functional subpopulations of β-cells emerge to control pulsative insulin secretion in the pancreatic islets of mice through calcium oscillations.

Clinical trials for exa-cel have shown promising results that it has been authorised by the FDA and MHRA for use in beta thalassemia and sickle cell disease. These successes make CRISPR technology, as ...